Dr. Schär, the Italian producer of specialized nutrition products, reported modest but steady growth in 2025, underscoring the resilience of its business model despite a volatile global environment.
The company said global revenue rose 1.3% to EUR632m, up from EUR624m in 2024, reflecting continued demand for gluten-free and other specialized dietary products.
The company attributes its performance to an integrated strategy that combines international expansion with the consolidation of local production facilities and sustained investment in research and development. Dr. Schär applies this approach throughout its value chain, from product development to manufacturing, supported by a network of subsidiaries operating in key markets worldwide. The structure allows the company to respond flexibly to shifting macroeconomic conditions while maintaining a focus on specialized nutrition.
Gluten-free products marketed under the Schär brand remain the company’s largest segment, complemented by offerings such as low-protein foods and products designed for therapeutic ketogenic diets. Growing global interest in specialized nutrition and food safety continues to support the sector’s expansion, particularly across Europe and North America.
In the United Kingdom, one of the company’s strategic markets, Dr. Schär employs 95 people across its Warrington and Glasgow operations. The facilities produce fresh bread and allergen-free baked goods tailored to local consumer preferences.
Investment has remained a central element of the company’s strategy. In 2025, Dr. Schär allocated EUR8.8m toward improvements in production and logistics efficiency. The company plans to significantly expand that effort in 2026, with EUR28m earmarked for new investments focused primarily on facilities in Italy, Spain and Germany. The spending reflects a targeted capital allocation strategy aimed at strengthening local production capacity while supporting growth in key markets.
Alongside industrial expansion, the company has also continued to emphasize sustainability initiatives. During 2025, Dr. Schär completed the transition to the exclusive use of cage-free eggs across its operations. At the beginning of 2026, its German production sites in Dreihausen and Apolda switched to certified clean electricity, bringing the total number of low-impact facilities in the group’s network to seven.
Additional environmental measures are planned for the coming year. Photovoltaic panels are scheduled to be installed at the company’s Austrian plant in Klagenfurt in 2026, part of a broader effort to advance a production model focused on innovation, efficiency and reduced environmental impact.
Find out more at: https://www.schaer.com/